Key Insights

Highlights

Treatment Research

1 treatments under study, led by Autologous Car123 T Lymphocytes

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Early Phase 1 (1)

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06765876Early Phase 1Active Not Recruiting

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

Showing all 1 trials

Research Network

Common Treatments

  • Autologous Car123 T Lymphocytes1

Active Sponsors

  • Institute Of Hematology And Blood Transfusion1
  • Institute of Hematology and Blood Transfusion, Czech Republic1

Top Investigators

Related Conditions

  • Precursor Cell Lymphoblastic Leukemialymphoma1
  • Leukemia Myeloid Acuteaml1
  • Myelodysplastic Syndromes Mds1
  • Blastic Plasmacytoid Dendritic Cell Neoplasm Bpdcn1

Activity Timeline